Q1A. Using the example (PDF) provided and the course readings, identify and explain the type of Business Network & Relationshipestablished by Sanofi and GSK to develop a vaccine (10 points). SANOFI Press Release Source: Sano (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021 PARIS and LONDON - April 14, 2020 - Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US. GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people. "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone." says Paul Hudson, Chief Executive Officer. Sanofi. "That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus." *This collaboration brings together two of the world's largest vaccines companies." says Emma Walmsley. Chief Executive Officer, GSK "By combining our scientific expertise, technologies and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from Covid- 19. The combination of a protein-based antigen together with an adjuvant is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer- lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life Media Relations Contact Marion Breyer Tel.: +33 (0)1 53 77 46 46 mrsanot.com Investor Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45 45 in sanoi.com Sench Porward-Locking Statement This greznisze contains forward-looking zinemans es defined in the Private Secondi Ligation Reform Act of 1935, emanded. Parward-looking at manteament that are not hanterice Decis. These statements include grglections and extend their underlying masungina, sementaragarding plena cjectives, intention and expectations with respect to future Anansieres aventuration, service gredet deriment and gentle and selements regarding butun periormente. Ponuersaking sements en generally identified by the word Bapacity and believes idees was blenz ander examina. Although Sunal' mengamand believes that the spections reflected in auch Marward-looking statement, Investors en cened the forward-looking intention and ment en ubject to variousnais and uncer, many of which are cette graditend generally beyond the control of Sure, the could cause curand development te mermalely from these apresedi,eringlid argralected by the ones logo and at. These and uncertainties include an ather things, the ones Internatin neesh and development future clical date and anys, including pet mig, decisions by regulatory authors, auch she FDA arthe GMA, regering whether and wherevery drug device or blalegice Eggleston the may be filled for En auch greduct and swel as their decisions regarding labeling and other matter that could affect the evenilebiliyor commercial potential of such greded candidates, the feet the product candidates reporved may not be commercial UCL, the future grove and commercial use of therapeute eilematives, Seaf Ebility to bentem sinna growth sportunities to completed the sections ander ab ein regulatory ciences, nice acted with intellectual property and any red pendling er future ingon and the ultimate outcome of such litigation, trends in exchange rates and gravning interest rates, vel economic and market conditions, the impact of global caruiana, including pensamies, coa! contements and sent change ther, the age rembaralunding these de arinted in the publicing with the SEC and the AMF made by Sonat, including those sted under "Rik Pestera" and Cestionary Shement Regering Forward-looking Students in Senell' annual report on Form 20-F for the year andled December 31, 2019. Other than es required by applicabim, Senadomat undertake any obligation to update arrave en onverdig inomation ar ainda mais Q1A. Using the example (PDF) provided and the course readings, identify and explain the type of Business Network & Relationshipestablished by Sanofi and GSK to develop a vaccine (10 points). SANOFI Press Release Source: Sano (EURONEXT: SAN) (NASDAQ: SNY) Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021 PARIS and LONDON - April 14, 2020 - Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US. GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people. "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone." says Paul Hudson, Chief Executive Officer. Sanofi. "That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus." *This collaboration brings together two of the world's largest vaccines companies." says Emma Walmsley. Chief Executive Officer, GSK "By combining our scientific expertise, technologies and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from Covid- 19. The combination of a protein-based antigen together with an adjuvant is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer- lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life Media Relations Contact Marion Breyer Tel.: +33 (0)1 53 77 46 46 mrsanot.com Investor Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45 45 in sanoi.com Sench Porward-Locking Statement This greznisze contains forward-looking zinemans es defined in the Private Secondi Ligation Reform Act of 1935, emanded. Parward-looking at manteament that are not hanterice Decis. These statements include grglections and extend their underlying masungina, sementaragarding plena cjectives, intention and expectations with respect to future Anansieres aventuration, service gredet deriment and gentle and selements regarding butun periormente. Ponuersaking sements en generally identified by the word Bapacity and believes idees was blenz ander examina. Although Sunal' mengamand believes that the spections reflected in auch Marward-looking statement, Investors en cened the forward-looking intention and ment en ubject to variousnais and uncer, many of which are cette graditend generally beyond the control of Sure, the could cause curand development te mermalely from these apresedi,eringlid argralected by the ones logo and at. These and uncertainties include an ather things, the ones Internatin neesh and development future clical date and anys, including pet mig, decisions by regulatory authors, auch she FDA arthe GMA, regering whether and wherevery drug device or blalegice Eggleston the may be filled for En auch greduct and swel as their decisions regarding labeling and other matter that could affect the evenilebiliyor commercial potential of such greded candidates, the feet the product candidates reporved may not be commercial UCL, the future grove and commercial use of therapeute eilematives, Seaf Ebility to bentem sinna growth sportunities to completed the sections ander ab ein regulatory ciences, nice acted with intellectual property and any red pendling er future ingon and the ultimate outcome of such litigation, trends in exchange rates and gravning interest rates, vel economic and market conditions, the impact of global caruiana, including pensamies, coa! contements and sent change ther, the age rembaralunding these de arinted in the publicing with the SEC and the AMF made by Sonat, including those sted under "Rik Pestera" and Cestionary Shement Regering Forward-looking Students in Senell' annual report on Form 20-F for the year andled December 31, 2019. Other than es required by applicabim, Senadomat undertake any obligation to update arrave en onverdig inomation ar ainda mais